Evidence map›Paper›PMID 29596326›Full record

ArticleCancers2018

Differentiation Therapy Targeting the β-Catenin/CBP Interaction in Pancreatic Cancer.

Philipp Manegold, Keane K Y Lai, Yongfeng Wu, Jia-Ling Teo, Heinz-Josef Lenz, Yuri S Genyk, Stephen J Pandol, Kaijin Wu, David P Lin, Yibu Chen and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 53 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Targeting CBP and p300: Emerging Anticancer Agents.Molecules (Basel, Switzerland) · 2024
    Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Targeting Transcription Factors in Cancer: From "Undruggable" to "Druggable".Methods in molecular biology (Clifton, N.J.) · 2023
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Philipp ManegoldNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA. philipp.manegold@uniklinik-freiburg.de.
Keane K Y LaiNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA. klai@coh.org.
Yongfeng WuNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA. wuyf001@163.com.
Jia-Ling TeoNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA. jteo@coh.org.
Heinz-Josef LenzNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA. LENZ@med.usc.edu.
Yuri S GenykDepartment of Surgery, University of Southern California, Los Angeles, CA 90033, USA. yuri.genyk@health.usc.edu.
Stephen J PandolSouthern California Research Center for Alcoholic Liver and Pancreatic Diseases and Cirrhosis, Department of Pathology, University of Southern California, Los Angeles, CA 90033, USA. Stephen.Pandol@cshs.org.
Kaijin WuNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA. kaijinwu@usc.edu.
David P LinDepartment of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA. dplin@hotmail.com.
Yibu ChenHealth Sciences Libraries, University of Southern California, Los Angeles, CA 90033, USA. yibuchen@usc.edu.
Cu NguyenNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA. cunguyen@coh.org.
Yi ZhaoNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA. yizhao@usc.edu.
Michael KahnNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA. mkahn@coh.org.
University of Southern California · USBeckman Research InstitutePathways Behavioral Services · USCity of Hope · US

Funding

Targeting diet-induced promotion of Kras-initiated pancreatic adenocarcinomaP01CA163200 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PANDOL, STEPHEN J. · 2012 to 2016
$6.2M
Pathophysiology, Epidemiology, and Prevention of Pancreatogenic Diabetes - Administrative SupplementU01DK108314 · NIDDK · CEDARS-SINAI MEDICAL CENTER · PI Mark Goodarzi, Stephen J. Pandol · 2015 to 2026
$6.1M
Stearoyl-CoA Desaturase in Alcohol-Promoted Liver TumorigenesisK08AA025112 · NIAAA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI LAI, KEANE · 2017 to 2021
$978k
NCI NIH HHS P01 CA163200NIAAA NIH HHS K08 AA025112NIDDK NIH HHS U01 DK108314
6 · The paper itself

Abstract

backgroundAlthough canonical Wnt signaling is known to promote tumorigenesis in pancreatic ductal adenocarcinoma (PDAC), a cancer driven principally by mutant AIM/

methodsTo investigate Wnt-mediated carcinogenesis in PDAC, we have used the specific small molecule CBP/β-catenin antagonist, ICG-001, which our lab identified and has extensively characterized, to examine its effects in human pancreatic cancer cells and in both an orthotopic mouse model and a human patient-derived xenograft (PDX) model of PDAC. RESULTS/

conclusionWe report for the first time that

Identifiers

PMID29596326
PMCPMC5923350
OpenAlexW2794656614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.